Pb1677 Sixteen Year's Experience of the Eortc 58951 protocol for the Treatment of Childhood Acute Lymphoblastic Leukemia in the South of Tunisia

Abstract

Background: Measurement of minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL) is integrated in treatment protocols due to it prognostic significance. In Ph+ B-ALL BCR-ABL1 transcripts are the preferential molecular targets for MRD assessment.